Aetion, a Manhattan startup with a software platform that assesses the effectiveness of drugs and other clinical interventions, has raised $36.4 million in a Series B round led by venture capital giant New Enterprise Associates.
Manhattan startup raises $36M for platform that can test drugs' effectiveness
Aetion uses real-world data to help drug companies and insurers make decisions
The latest round, which included the corporate VC arm of biopharma company Amgen, brings Aetion's total funding from private investors to $50 million.
Existing investors Flare Capital Partners, Lakestar and Oxeon Ventures also participated.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.